'use strict';

/* jshint -W098 */
angular.module('mean.trialmatch').controller('TrialmatchController', ['$scope', 'Global', 'Trialmatch',
  function($scope, Global, Trialmatch) {
    $scope.global = Global;
    $scope.package = {
      name: 'trialmatch'
    };

    $scope.clinicalTrials = [
  // {
  //   'FIELD1':'link',
  //   'FIELD2':'link/_text',
  //   'FIELD3':'link/_title',
  //   'FIELD4':'number',
  //   'FIELD5':'value_1',
  //   'FIELD6':'value_2',
  //   'FIELD7':'value_3',
  //   'FIELD8':'body3_value_1',
  //   'FIELD9':'datatable_description_1',
  //   'FIELD10':'body3_value_2',
  //   'FIELD11':'datatable_description_2',
  //   'FIELD12':'_PAGE_NUMBER'
  // },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00425750?rank=1',
    'FIELD2':'Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer',
    'FIELD3':'Show study NCT00425750: Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer',
    'FIELD4':'1',
    'FIELD5':'Completed',
    'FIELD6':'Has Results',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Head and Neck Cancer',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: bortezomib; Drug: docetaxel; Other: laboratory biomarker analysis; Other: pharmacological study',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00781950?rank=2',
    'FIELD2':'Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease',
    'FIELD3':'Show study NCT00781950: Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease',
    'FIELD4':'2',
    'FIELD5':'Active, not recruiting',
    'FIELD6':'Has Results',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Peripheral Arterial Disease',
    'FIELD10':'Intervention:',
    'FIELD11':'Dietary Supplement: Flaxseed',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT02080650?rank=3',
    'FIELD2':'Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)',
    'FIELD3':'Show study NCT02080650: Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)',
    'FIELD4':'3',
    'FIELD5':'Recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Conditions:',
    'FIELD9':'Prostate Cancer; Renal Cell Carcinoma; Bladder Cancer; Colorectal Cancer; Gastric Cancer; Pancreatic Cancer; Non-small Cell Lung Cancer',
    'FIELD10':'Interventions:',
    'FIELD11':'Device: Mesenchymal-marker based ferrofluid (c-MET); Device: Epithelial cell adhesion molecule (EpCAM) ferrofluid',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00164450?rank=4',
    'FIELD2':'TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection',
    'FIELD3':'Show study NCT00164450: TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection',
    'FIELD4':'4',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Tuberculosis',
    'FIELD10':'Intervention:',
    'FIELD11':'Drug: Rifapentine + isoniazid once weekly for 3 months',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00464750?rank=5',
    'FIELD2':'Study on the Repeatability of Cardiac Output Measurements Dependence of Temperature of Injectate',
    'FIELD3':'Show study NCT00464750: Study on the Repeatability of Cardiac Output Measurements Dependence of Temperature of Injectate',
    'FIELD4':'5',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Thermodilution, Cardiac Output',
    'FIELD10':'Intervention:',
    'FIELD11':'Device: Pulmonary artery catheter',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01840150?rank=6',
    'FIELD2':'Nanoscale Artificial Nose in Monitoring Response and Detecting Recurrence After Surgery or Radiation Therapy in Patients With Stage I or Stage II Non-Small Cell Lung Cancer',
    'FIELD3':'Show study NCT01840150: Nanoscale Artificial Nose in Monitoring Response and Detecting Recurrence After Surgery or Radiation Therapy in Patients With Stage I or Stage II Non-Small Cell Lung Cancer',
    'FIELD4':'6',
    'FIELD5':'Recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Conditions:',
    'FIELD9':'Stage IA Non-small Cell Lung Cancer; Stage IB Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer',
    'FIELD10':'Interventions:',
    'FIELD11':'Procedure: breath test; Other: laboratory biomarker analysis',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01266850?rank=7',
    'FIELD2':'Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules',
    'FIELD3':'Show study NCT01266850: Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules',
    'FIELD4':'7',
    'FIELD5':'Completed',
    'FIELD6':'Has Results',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Rotavirus Infection',
    'FIELD10':'Interventions:',
    'FIELD11':'Biological: Rotarix®; Biological: RotaTeq®',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00099450?rank=8',
    'FIELD2':'Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers',
    'FIELD3':'Show study NCT00099450: Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers',
    'FIELD4':'8',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Cardiovascular Disease',
    'FIELD10':'Intervention:',
    'FIELD11':'Drug: INS50589 Intravenous Infusion',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01827150?rank=9',
    'FIELD2':'The Influence of Energy Drinks on the Blood Oxygenation Concentration of the Optic Nerve',
    'FIELD3':'Show study NCT01827150: The Influence of Energy Drinks on the Blood Oxygenation Concentration of the Optic Nerve',
    'FIELD4':'9',
    'FIELD5':'Unknown',
    'FIELD6':'',
    'FIELD7':'†',
    'FIELD8':'Condition:',
    'FIELD9':'Healthy',
    'FIELD10':'Intervention:',
    'FIELD11':'Drug: Redbull, energy drink',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00701350?rank=10',
    'FIELD2':'Biomarkers of Intra-amniotic Infection in Women With Preterm Premature Ruptured Amniotic Membranes',
    'FIELD3':'Show study NCT00701350: Biomarkers of Intra-amniotic Infection in Women With Preterm Premature Ruptured Amniotic Membranes',
    'FIELD4':'10',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Conditions:',
    'FIELD9':'Intra-amniotic Infection; Preterm Birth',
    'FIELD10':'Intervention:',
    'FIELD11':'',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00564850?rank=11',
    'FIELD2':'Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty',
    'FIELD3':'Show study NCT00564850: Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty',
    'FIELD4':'11',
    'FIELD5':'Completed',
    'FIELD6':'Has Results',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Precocious Puberty',
    'FIELD10':'Intervention:',
    'FIELD11':'Drug: Triptorelin pamoate 11.25mg (Decapeptyl® SR)',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00950950?rank=12',
    'FIELD2':'A Study to Evaluate the Effect of AMG 785 on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass',
    'FIELD3':'Show study NCT00950950: A Study to Evaluate the Effect of AMG 785 on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass',
    'FIELD4':'12',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Osteopenia',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: AMG 785; Drug: Placebo',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01192750?rank=13',
    'FIELD2':'Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab',
    'FIELD3':'Show study NCT01192750: Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab',
    'FIELD4':'13',
    'FIELD5':'Unknown',
    'FIELD6':'',
    'FIELD7':'†',
    'FIELD8':'Condition:',
    'FIELD9':'Head and Neck Cancer',
    'FIELD10':'Interventions:',
    'FIELD11':'Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: medical chart review',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00203450?rank=14',
    'FIELD2':'Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial',
    'FIELD3':'Show study NCT00203450: Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial',
    'FIELD4':'14',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Obesity',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: Zonegran; Drug: Placebo',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT02018250?rank=15',
    'FIELD2':'Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)',
    'FIELD3':'Show study NCT02018250: Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)',
    'FIELD4':'15',
    'FIELD5':'Suspended',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Treatment Against the Lethal Effects of Nerve Agent Intoxication',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: MMB4 DMS; Drug: Placebo',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01898650?rank=16',
    'FIELD2':'MRI for Non-invasive Evaluation of Brain Stress',
    'FIELD3':'Show study NCT01898650: MRI for Non-invasive Evaluation of Brain Stress',
    'FIELD4':'16',
    'FIELD5':'Recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Craniosynostosis',
    'FIELD10':'Intervention:',
    'FIELD11':'Other: MR scan',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00645450?rank=17',
    'FIELD2':'PTSD Symptom Reduction by Propranolol Given After Trauma Memory Activation',
    'FIELD3':'Show study NCT00645450: PTSD Symptom Reduction by Propranolol Given After Trauma Memory Activation',
    'FIELD4':'17',
    'FIELD5':'Terminated',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Posttraumatic Stress Disorders',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: Propranolol; Drug: Placebo',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00902850?rank=18',
    'FIELD2':'One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens',
    'FIELD3':'Show study NCT00902850: One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens',
    'FIELD4':'18',
    'FIELD5':'Completed',
    'FIELD6':'Has Results',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Myopia',
    'FIELD10':'Interventions:',
    'FIELD11':'Device: SofLens Daily Disposable; Device: Marketed 1 Day Contact Lens',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00170950?rank=19',
    'FIELD2':'Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension',
    'FIELD3':'Show study NCT00170950: Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension',
    'FIELD4':'19',
    'FIELD5':'Terminated',
    'FIELD6':'Has Results',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Hypertension',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2; Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1; Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2; Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter',
    'FIELD12':'1'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01339650?rank=21',
    'FIELD2':'Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer',
    'FIELD3':'Show study NCT01339650: Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer',
    'FIELD4':'21',
    'FIELD5':'Active, not recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Conditions:',
    'FIELD9':'Fallopian Tube; Primary Peritoneal Cancer; Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian',
    'FIELD10':'Intervention:',
    'FIELD11':'Drug: ABT-767',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01390350?rank=22',
    'FIELD2':'Ilaris® Effects in Schnitzler Syndrome (ILESCH)',
    'FIELD3':'Show study NCT01390350: Ilaris® Effects in Schnitzler Syndrome (ILESCH)',
    'FIELD4':'22',
    'FIELD5':'Active, not recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Schnitzler Syndrome',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: Canakinumab; Drug: Placebo',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01312350?rank=23',
    'FIELD2':'Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)',
    'FIELD3':'Show study NCT01312350: Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)',
    'FIELD4':'23',
    'FIELD5':'Recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Hypopharyngeal Cancer',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: neoadjuvant docetaxel/cisplatin/fluorouracil; Drug: No treatment before definitive CCRT',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00403650?rank=24',
    'FIELD2':'Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension',
    'FIELD3':'Show study NCT00403650: Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension',
    'FIELD4':'24',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Conditions:',
    'FIELD9':'Sarcoidosis; Pulmonary Arterial Hypertension',
    'FIELD10':'Intervention:',
    'FIELD11':'Drug: Iloprost',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00390650?rank=25',
    'FIELD2':'A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder',
    'FIELD3':'Show study NCT00390650: A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder',
    'FIELD4':'25',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Anxiety',
    'FIELD10':'Intervention:',
    'FIELD11':'Drug: Saredutant',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT02243150?rank=26',
    'FIELD2':'Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1',
    'FIELD3':'Show study NCT02243150: Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1',
    'FIELD4':'26',
    'FIELD5':'Recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Healthy Volunteers',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: G1T28-1 (CDK 4/6 Inhibitor); Drug: Placebo',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01842750?rank=27',
    'FIELD2':'The Use of Rectal Balloons in Radical Pelvic Radiotherapy - a Feasibility Study',
    'FIELD3':'Show study NCT01842750: The Use of Rectal Balloons in Radical Pelvic Radiotherapy - a Feasibility Study',
    'FIELD4':'27',
    'FIELD5':'Recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Prostate Cancer',
    'FIELD10':'Intervention:',
    'FIELD11':'Device: Endorectal Balloon insertion',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT02232750?rank=28',
    'FIELD2':'Evaluation of CPD MNV as an Aid in the Diagnosis and Risk Assessment of Sepsis (Protocol # Sepsis 1-14)',
    'FIELD3':'Show study NCT02232750: Evaluation of CPD MNV as an Aid in the Diagnosis and Risk Assessment of Sepsis (Protocol # Sepsis 1-14)',
    'FIELD4':'28',
    'FIELD5':'Recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Sepsis, Severe Sepsis and Septic Shock',
    'FIELD10':'Intervention:',
    'FIELD11':'',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01260350?rank=29',
    'FIELD2':'Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3',
    'FIELD3':'Show study NCT01260350: Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3',
    'FIELD4':'29',
    'FIELD5':'Completed',
    'FIELD6':'Has Results',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Chronic Hepatitis C Infection',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: SOF; Drug: RBV; Drug: PEG; Drug: LDV; Drug: GS-9669; Drug: LDV/SOF',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00069550?rank=30',
    'FIELD2':'Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome',
    'FIELD3':'Show study NCT00069550: Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome',
    'FIELD4':'30',
    'FIELD5':'Unknown',
    'FIELD6':'',
    'FIELD7':'†',
    'FIELD8':'Condition:',
    'FIELD9':'Rett Syndrome',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: dextromethorphan; Drug: donepezil hydrochloride',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00720850?rank=31',
    'FIELD2':'Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)',
    'FIELD3':'Show study NCT00720850: Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)',
    'FIELD4':'31',
    'FIELD5':'Terminated',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Conditions:',
    'FIELD9':'Myelodysplastic Syndromes; Acute Myelogenous Leukemia',
    'FIELD10':'Intervention:',
    'FIELD11':'Drug: lenalidomide',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01547650?rank=32',
    'FIELD2':'Evaluation of Plasma Volume Using Ultrasound in Disorders of Fluid With Sodium',
    'FIELD3':'Show study NCT01547650: Evaluation of Plasma Volume Using Ultrasound in Disorders of Fluid With Sodium',
    'FIELD4':'32',
    'FIELD5':'Active, not recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Other Diagnoses and Conditions',
    'FIELD10':'Intervention:',
    'FIELD11':'Other: Calculated CVP by using cardiac echogram',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT02072850?rank=33',
    'FIELD2':'Detection and Significance of Heart Injury in ST Elevation Myocardial Infarction.',
    'FIELD3':'Show study NCT02072850: Detection and Significance of Heart Injury in ST Elevation Myocardial Infarction.',
    'FIELD4':'33',
    'FIELD5':'Active, not recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Acute ST-elevation Myocardial Infarction',
    'FIELD10':'Interventions:',
    'FIELD11':'Device: Coronary pressure wire; Other: Magnetic resonance imaging of the heart',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00921050?rank=34',
    'FIELD2':'Subclinical Hypothyroidism and Mind in the Elderly',
    'FIELD3':'Show study NCT00921050: Subclinical Hypothyroidism and Mind in the Elderly',
    'FIELD4':'34',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Subclinical Hypothyroidism',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: levothyroxine sodium; Drug: excipient without levothyroxine (placebo)',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01810250?rank=35',
    'FIELD2':'Endurant for Challenging Anatomy: Global Experience Registry',
    'FIELD3':'Show study NCT01810250: Endurant for Challenging Anatomy: Global Experience Registry',
    'FIELD4':'35',
    'FIELD5':'Recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Abdominal Aortic Aneurysms With Challenging Anatomy',
    'FIELD10':'Intervention:',
    'FIELD11':'Device: Endurant Stent Graft',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01873950?rank=36',
    'FIELD2':'Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects',
    'FIELD3':'Show study NCT01873950: Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects',
    'FIELD4':'36',
    'FIELD5':'Active, not recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Drug-induced Surface ECG Changes',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: Ranolazine; Drug: Dofetilide; Drug: Verapamil; Drug: Quinidine sulfate; Drug: Placebo',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00417950?rank=37',
    'FIELD2':'Additional Glucose Lowering and Anti-Inflammatory Effects by Acarbose and Alcohol in Subjects With Impaired Glucose Tolerance or Mild Type 2 Diabetes',
    'FIELD3':'Show study NCT00417950: Additional Glucose Lowering and Anti-Inflammatory Effects by Acarbose and Alcohol in Subjects With Impaired Glucose Tolerance or Mild Type 2 Diabetes',
    'FIELD4':'37',
    'FIELD5':'Unknown',
    'FIELD6':'',
    'FIELD7':'†',
    'FIELD8':'Conditions:',
    'FIELD9':'Diabetes Mellitus; Impaired Glucose Tolerance',
    'FIELD10':'Intervention:',
    'FIELD11':'Drug: Acarbose',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00931450?rank=38',
    'FIELD2':'Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer',
    'FIELD3':'Show study NCT00931450: Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer',
    'FIELD4':'38',
    'FIELD5':'Unknown',
    'FIELD6':'',
    'FIELD7':'†',
    'FIELD8':'Condition:',
    'FIELD9':'Breast Cancer',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: exemestane; Drug: sunitinib malate; Other: placebo',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01443650?rank=39',
    'FIELD2':'Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects',
    'FIELD3':'Show study NCT01443650: Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects',
    'FIELD4':'39',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Hypercholesterolemia',
    'FIELD10':'Intervention:',
    'FIELD11':'Drug: alirocumab SAR236553 (REGN727)',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00445250?rank=40',
    'FIELD2':'The Role of Calcipotriol as Radioprotector of Skin',
    'FIELD3':'Show study NCT00445250: The Role of Calcipotriol as Radioprotector of Skin',
    'FIELD4':'40',
    'FIELD5':'Unknown',
    'FIELD6':'',
    'FIELD7':'†',
    'FIELD8':'Condition:',
    'FIELD9':'Radiodermatitis',
    'FIELD10':'Intervention:',
    'FIELD11':'Drug: Calcipotriol',
    'FIELD12':'2'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01786850?rank=41',
    'FIELD2':'Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer',
    'FIELD3':'Show study NCT01786850: Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer',
    'FIELD4':'41',
    'FIELD5':'Available',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Conditions:',
    'FIELD9':'Pancreas; Cancer; Locally Advanced Pancreatic Cancer; Non-invasive Treatment',
    'FIELD10':'Intervention:',
    'FIELD11':'Procedure: Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)',
    'FIELD12':'3'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01587950?rank=42',
    'FIELD2':'The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity',
    'FIELD3':'Show study NCT01587950: The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity',
    'FIELD4':'42',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Conditions:',
    'FIELD9':'Dentinal Hypersensitivity; Dental Pain',
    'FIELD10':'Interventions:',
    'FIELD11':'Drug: Potassium Nitrate; Drug: Placebo',
    'FIELD12':'3'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01651650?rank=43',
    'FIELD2':'An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device',
    'FIELD3':'Show study NCT01651650: An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device',
    'FIELD4':'43',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Asthma',
    'FIELD10':'Intervention:',
    'FIELD11':'Device: Inhalation through Chiesi NEXThaler DPI',
    'FIELD12':'3'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01899950?rank=44',
    'FIELD2':'Longitudinal Study of Cognition With Niemann-Pick Disease, Type C',
    'FIELD3':'Show study NCT01899950: Longitudinal Study of Cognition With Niemann-Pick Disease, Type C',
    'FIELD4':'44',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Niemann-Pick Disease, Type C',
    'FIELD10':'Intervention:',
    'FIELD11':'',
    'FIELD12':'3'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01976650?rank=45',
    'FIELD2':'Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea',
    'FIELD3':'Show study NCT01976650: Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea',
    'FIELD4':'45',
    'FIELD5':'Active, not recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Retinal Vein Occlusion',
    'FIELD10':'Intervention:',
    'FIELD11':'Drug: dexamethasone 700 ㎍ intravitreal implant',
    'FIELD12':'3'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT02197650?rank=46',
    'FIELD2':'Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase',
    'FIELD3':'Show study NCT02197650: Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase',
    'FIELD4':'46',
    'FIELD5':'Available',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Acute Lymphoblastic Leukemia',
    'FIELD10':'Intervention:',
    'FIELD11':'Drug: suspension of erythrocytes encapsulating L-asparaginase',
    'FIELD12':'3'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT00930150?rank=47',
    'FIELD2':'Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network',
    'FIELD3':'Show study NCT00930150: Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network',
    'FIELD4':'47',
    'FIELD5':'Completed',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'Schizophrenia',
    'FIELD10':'Interventions:',
    'FIELD11':'Behavioral: Targeted cognitive training; Behavioral: Computer control; Behavioral: Bridging groups; Behavioral: Health and wellness groups',
    'FIELD12':'3'
  },
  {
    'FIELD1':'https://clinicaltrials.gov/ct2/show/NCT01686750?rank=48',
    'FIELD2':'Integrated Care Centers to Improve HIV Outcomes in Vulnerable Indian Populations',
    'FIELD3':'Show study NCT01686750: Integrated Care Centers to Improve HIV Outcomes in Vulnerable Indian Populations',
    'FIELD4':'48',
    'FIELD5':'Recruiting',
    'FIELD6':'',
    'FIELD7':'',
    'FIELD8':'Condition:',
    'FIELD9':'HIV Infection',
    'FIELD10':'Intervention:',
    'FIELD11':'Behavioral: Integrated care centers',
    'FIELD12':'3'
  }
];
  }
]);
